Duchier J, Guinot P
Arch Mal Coeur Vaiss. 1979 Oct;72(10):1151-4.
This schematic analysis demonstrates the great increase in the cost and time required to develop a new molecule, factors which therefore limit the development of new therapeutic methods. The patent period is shorter so that the period of commercialisation of a product by a single drug company is more and more limited. Therefore the situation may occur where the costs of development will no longer be covered. (In addition, the costs of research not leading to a marketable product have not been taken into account).
这种示意图分析表明，开发一种新分子所需的成本和时间大幅增加，因此这些因素限制了新治疗方法的开发。专利期限缩短，导致单个制药公司产品的商业化期限越来越有限。因此，可能会出现开发成本无法得到弥补的情况。（此外，未考虑未产生适销产品的研究成本）
